

# Summary of Product Characteristics

## 1 NAME OF THE VETERINARY MEDICINAL PRODUCT

Clavaseptin 50 mg palatable tablets for dogs and cats

## 2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each tablet contains:

### Active substances:

Amoxicillin (as amoxicillin trihydrate) 0 mg

Clavulanic acid (as potassium salt) 10 mg

### Excipients

Brown iron oxide (E172) 0.095 mg

For the full list of excipients, see section 6.1.

## 3 PHARMACEUTICAL FORM

Tablet.

Beige scored tablet that can be divided into equal halves.

## 4 CLINICAL PARTICULARS

### 4.1 Target Species

Dogs and cats.

### 4.2 Indications for use, specifying the target species

In dogs: treatment or adjunctive treatment of periodontal infections caused by bacteria susceptible to amoxicillin in combination with clavulanic acid i.e. *Pasteurella* spp., *Streptococcus* spp. and *Escherichia coli*.

In cats: treatment of skin infections (including wounds and abscesses) caused by bacteria susceptible to amoxicillin in combination with clavulanic acid i.e. *Pasteurella* spp., *Staphylococcus* spp., *Streptococcus* spp. and *Escherichia coli*.

### 4.3 Contraindications

Do not use in animals with known hypersensitivity to penicillins or other substances of the  $\beta$ -lactam group or to any of the excipients.

Do not administer to gerbils, guinea pigs, hamsters, rabbits and chinchillas.

Do not administer to horses and ruminating animals.

Do not use in animals with serious dysfunction of the kidneys accompanied by anuria or oliguria.

Do not use in cases of known resistance to the combination of amoxicillin and clavulanic acid.

#### **4.4 Special warnings for each target species**

None.

#### **4.5 Special precautions for use**

##### Special precautions for use in animals

In addition to section 4.3 contraindications:

In animals with impaired liver and kidney function, the use of the product should be subject to a risk/benefit evaluation by the veterinary surgeon and the posology evaluated carefully.

Caution is advised in the use in small herbivores other than those in 4.3.

Use of the product should be based on susceptibility testing.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to amoxicillin/clavulanic acid and may decrease the effectiveness of treatment with other  $\beta$ -lactam antibiotics, due to the potential for cross resistance. Use of the product should take into account official and local antimicrobial policies. Do not use in cases of bacteria sensitive to narrow spectrum penicillins or to amoxicillin as a single substance.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals

Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Hypersensitivity to penicillins may lead to cross reactions to cephalosporins and *vice versa*. Allergic reactions to these substances may occasionally be serious.

1. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.
  2. Handle this product with great care to avoid exposure, taking all recommended precautions.
  3. If you develop symptoms following exposure, such as skin rash, you should seek medical advice and show the doctor this warning.
- Swelling of the face, lips or eyes or difficulty breathing are more serious symptoms and require urgent medical attention.
- Wash hands after handling the tablets.

#### 4.6 Adverse reactions (frequency and seriousness)

Vomiting and diarrhoea may be observed. Treatment may be discontinued depending on the severity of the undesirable effects and a benefit/risk evaluation by the veterinary surgeon.

Hypersensitivity reactions (allergic skin reactions, anaphylaxis) may be observed. In these cases, administration should be discontinued and a symptomatic treatment given.

#### 4.7 Use during pregnancy, lactation or lay

The safety of the product has not been established during pregnancy and lactation. Laboratory studies in rats have not produced any evidence of teratogenic, foetotoxic or maternotoxic effects. Use the product only accordingly to the benefit/risk assessment by the responsible veterinarian.

#### 4.8 Interaction with other medicinal products and other forms of interactions

The bactericidal activity of amoxicillin may be reduced by the simultaneous use of bacteriostatic substances such as macrolides, tetracyclines, sulfonamides and chloramphenicol.

The potential for allergic cross-reactivity with other penicillins should be considered. Penicillins may increase the effect of aminoglycosides.

#### 4.9 Amounts to be administered and administration route

The recommended dose of the product is 10 mg amoxicillin /2.5 mg clavulanic acid per kg body weight twice a day by the oral route in dogs and cats, i.e. 1 tablet per 4 kg body weight every 12 h, according to the following table:

Bodyweight (kg)	Number of tablets twice daily
[ 1.0- 2.0 ]	½
[ 2.1- 4.0 ]	1
[ 4.1- 6.0 ]	1 ½
[ 6.1- 8.0 ]	2

In severe infections in each target species, the dose may be doubled to 20 mg amoxicillin/5 mg clavulanic acid/kg body weight twice daily.

##### Duration of treatment:

- 7 days for the treatment of periodontal infections in dogs.
  - 7 days for the treatment of skin infections in cats (including wounds and abscesses).
- The clinical status of animals should be re-evaluated after 7 days and the treatment prolonged for a further 7 days if necessary. Severe cases of skin infection may require

an even longer duration of treatment and this should be at the discretion of the responsible veterinarian.

To ensure the correct dosage, body weight should be determined as accurately as possible to avoid under-dosing.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

At three times the recommended dose for a period of 28 days, a decrease in cholesterol values and episodes of vomiting were observed in cats and diarrhoea was observed in dogs. In the event of an overdose symptomatic treatment is advised.

#### **4.11 Withdrawal period(s)**

Not applicable.

### **5 PHARMACOLOGICAL or IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: anti-infective for systemic use; amoxicillin and enzyme inhibitor.

ATCvet code: QJ01CR02

#### **5.1 Pharmacodynamic properties**

Amoxicillin is an aminobenzylpenicillin from the  $\beta$ -lactam penicillin family which prevents the bacterial cell wall formation by interfering with the final step of peptidoglycan synthesis.

Clavulanic acid is an irreversible inhibitor of intracellular and extracellular  $\beta$ -lactamases which protects amoxicillin from inactivation by many  $\beta$ -lactamases. Amoxicillin/clavulanate has a wide range of activity which includes  $\beta$ -lactamase producing strains of both Gram-positive and Gram-negative aerobes, facultative anaerobes and obligate anaerobes.

Amoxicillin/clavulanic acid breakpoints (NCCLS/2002):

*Staphylococci*: sensitive: MIC  $\leq$  4/2  $\mu$ g/ml, resistant: MIC  $\geq$  8/4  $\mu$ g/ml

Other organisms: sensitive: MIC  $\leq$  8/4  $\mu$ g/ml, resistant: MIC  $\geq$  32/16  $\mu$ g/ml

In dog periodontal infections in Europe (isolates of the year 2002 from France, Germany and Belgium) amoxicillin/clavulanic acid combination in a ratio 2/1 showed the following data on sensitivity:

*Pasteurellaceae*: MIC<sub>90</sub>: 0.4/0.2  $\mu$ g/ml,

*Streptococcus* spp.: MIC<sub>90</sub>: 0.4/0.2  $\mu$ g/ml,

*Escherichia coli*: MIC<sub>90</sub>: 5.3/2.6  $\mu$ g/ml,

In cat skin infections including wounds and abscesses in Europe (isolates of the year 2002 from France, Germany and Belgium) amoxicillin/clavulanic acid combination in a ratio 2/1 showed the following data on sensitivity:

*Pasteurellaceae*: MIC<sub>90</sub>: 0.66/0.3 µg/ml,  
*Staphylococcaceae*: MIC<sub>90</sub>: 0.4/0.2 µg/ml,  
*Streptococcaceae*: MIC<sub>90</sub>: 0.4/0.2 µg/ml,  
*Escherichia coli*: MIC<sub>90</sub>: 7.0/3.5 µg/ml,

Only 1.5 % of all isolated strains were resistant.

Resistance to β-lactam antibiotics is mainly mediated by β-lactamases which hydrolyze antibiotics such as amoxicillin.

Susceptibility and resistance patterns can vary with geographical area and bacterial strain, and may change over time.

## 5.2 Pharmacokinetic particulars

After oral administration at the recommended dose in dogs and cats, the absorption of amoxicillin and clavulanic acid is fast. In dogs, the maximum plasma concentration of amoxicillin of 8.5 µg/ml is reached in 1.4 h and the maximum plasma concentration of clavulanic acid of 0.9 µg/ml is reached in 0.9 h. Half life is 1 hour in dogs for both substances.

In cats, the maximum plasma concentration of amoxicillin of 6.6 µg/ml is reached in 1.8 h and the maximum plasma concentration of clavulanic acid of 3.7 µg/ml is reached in 0.75 h.

Half life is 1 to 2 hours in cats for both substances.

Elimination is also fast. 12 % of the amoxicillin and 17 % of clavulanic acid is excreted in the urine. The remainder is excreted as inactive metabolites.

After repeated oral administration of the recommended dose in dogs and cats, there is no accumulation of amoxicillin or clavulanic acid and the steady state is reached rapidly after first administration.

## 6 PHARMACEUTICAL PARTICULARS

### 6.1 List of excipients

Brown iron oxide E172  
Crospovidone  
Povidone K25  
Silicon dioxide  
Microcrystalline cellulose  
Liver aroma

Yeast aroma  
Magnesium stearate  
Hypromellose

## **6.2 Major incompatibilities**

None known.

## **6.3 Shelf-life**

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years  
Shelf life after first opening the immediate packaging: 16 hours

## **6.4 Special precautions for storage**

Do not store above 25°C. Store in the original package.  
Return any halved tablet to the opened blister-pack and use within 16 hours.

## **6.5 Nature and composition of immediate packaging**

Aluminium/aluminium blister pack with 10 tablets/blister  
Cardboard box: Pack sizes of 10, 20, 50, 100, 120, 150, 200, 250, 300, 400, 500, 600, 750 and 1000 tablets  
Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7 MARKETING AUTHORISATION HOLDER**

Vetoquinol Ireland Limited  
First Floor  
Segrave House  
19/20 Earlsfort Terrace  
Dublin 2  
Ireland

## **8 MARKETING AUTHORISATION NUMBER(S)**

VPA10983/048/001

**9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 21 October 2005

Date of last renewal: 20 August 2010

**10 DATE OF REVISION OF THE TEXT**

October 2018